BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3349463)

  • 1. Effects of antileukemia agents on nuclear matrix-bound DNA replication in CCRF-CEM leukemia cells.
    Fernandes DJ; Smith-Nanni C; Paff MT; Neff TA
    Cancer Res; 1988 Apr; 48(7):1850-5. PubMed ID: 3349463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
    Fernandes DJ; Danks MK; Beck WT
    Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase II cleavable complex formation within DNA loop domains.
    Lambert JM; Fernandes DJ
    Biochem Pharmacol; 2000 Jul; 60(1):101-9. PubMed ID: 10807951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
    Qiu J; Catapano CV; Fernandes DJ
    Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
    Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
    Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerase II isozymes involved in anticancer drug action and resistance.
    Fernandes DJ; Qiu J; Catapano CV
    Adv Enzyme Regul; 1995; 35():265-81. PubMed ID: 7572348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.
    Danks MK; Qiu J; Catapano CV; Schmidt CA; Beck WT; Fernandes DJ
    Biochem Pharmacol; 1994 Nov; 48(9):1785-95. PubMed ID: 7980648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
    Kim R; Beck WT
    Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of DNA with the nuclear lamina in Ehrlich ascites tumor cells.
    Krachmarov C; Iovcheva C; Hancock R; Dessev G
    J Cell Biochem; 1986; 31(1):59-74. PubMed ID: 3722277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis.
    Chitambar CR; Wereley JP
    Cancer Res; 1995 Oct; 55(19):4361-6. PubMed ID: 7671248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis.
    Hedley D; Rugg C; Musgrove E; Taylor I
    J Cell Physiol; 1985 Jul; 124(1):61-6. PubMed ID: 2413049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA.
    Lin JH; Castora FJ
    Arch Biochem Biophys; 1995 Dec; 324(2):293-9. PubMed ID: 8554321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermia blocks DNA processing at the nuclear matrix.
    Warters RL
    Radiat Res; 1988 Aug; 115(2):258-72. PubMed ID: 3406367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells.
    Minford J; Kerrigan D; Nichols M; Shackney S; Zwelling LA
    Cancer Res; 1984 Dec; 44(12 Pt 1):5583-93. PubMed ID: 6208999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effects of ciprofloxacin and the topoisomerase II inhibitors, m-AMSA and nalidixic acid, on DNA repair in cultured rat liver cells.
    Rosen JE; Schluter G; Williams GM
    Toxicol Appl Pharmacol; 1996 Oct; 140(2):254-63. PubMed ID: 8887441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of replication foci and nuclear matrix during S phase in Allium cepa L. cells.
    Samaniego R; de la Torre C; Moreno Díaz de la Espina S
    Planta; 2002 Jun; 215(2):195-204. PubMed ID: 12029468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A; Finlay GJ; Baguley BC
    Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.